Ovid Therapeutics Inc. (OVID)
| Market Cap | 423.67M +1,825.8% |
| Revenue (ttm) | 7.12M +1,199.6% |
| Net Income | -24.07M |
| EPS | -0.27 |
| Shares Out | 186.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,348,112 |
| Open | 2.420 |
| Previous Close | 2.420 |
| Day's Range | 2.270 - 2.490 |
| 52-Week Range | 0.285 - 3.105 |
| Beta | 0.18 |
| Analysts | Strong Buy |
| Price Target | 5.47 (+140.97%) |
| Earnings Date | May 12, 2026 |
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's d... [Read more]
Financial Performance
In 2025, Ovid Therapeutics's revenue was $7.25 million, an increase of 1181.27% compared to the previous year's $566,000. Losses were -$17.14 million, -34.01% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price target is $5.47, which is an increase of 140.97% from the latest price.
News
Ovid Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The company is advancing a diversified pipeline of small molecule therapies for neurological and neuropsychiatric disorders, with OV329 and OV4071 as lead assets. Key clinical milestones are expected in the next 6–24 months, supported by strong financial runway and a strategic approach to partnerships.
Ovid Therapeutics Transcript: AGM 2026
The meeting covered director election, executive compensation, and auditor ratification, with all proposals approved. No shareholder questions were raised, and quorum was established with 75.7% of shares represented.
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un...
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un...
Ovid Therapeutics price target raised to $7 from $5 at Roth Capital
Roth Capital raised the firm’s price target on Ovid Therapeutics (OVID) to $7 from $5 and keeps a Buy rating on the shares. The firm is updating its discount cash…
Ovid Therapeutics reports Q1 EPS (12c), consensus (11c)
“Our first quarter reflected focused execution and continued progress across our pipeline of potentially transformative small molecule medicines for intractable brain conditions,” stated Meg Alexander...
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safet...
Ovid Therapeutics Quarterly report: Q1 2026
Ovid Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Ovid Therapeutics Earnings release: Q1 2026
Ovid Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Ovid Therapeutics Slides: Corporate presentation
Ovid Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Ovid Therapeutics Proxy statement: Proxy filing
Ovid Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Ovid Therapeutics Proxy statement: Proxy filing
Ovid Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Ovid Therapeutics files to sell 29.86M shares of common stock for holders
16:33 EDT Ovid Therapeutics (OVID) files to sell 29.86M shares of common stock for holders
Ovid Therapeutics Registration statement: Registration filing
Ovid Therapeutics filed a registration statement on April 21, 2026, providing details about a securities offering with the SEC.
Ovid Therapeutics Transcript: Status update
KCC2 direct activation is a transformative approach for psychotic disorders, with OV4071 showing strong preclinical efficacy and safety. The clinical strategy uses translational biomarkers for rapid proof-of-concept in schizophrenia, Parkinson’s disease psychosis, and Lewy body dementia, backed by broad IP and significant commercial potential.
Ovid Therapeutics Slides: Status update
Ovid Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 14, 2026.
Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Ovid Therapeutics (OVID) to $4 from $2 and keeps a Buy rating on the shares. The company’s OV4071 oral KCC2 candidate is…
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod...
Ovid Therapeutics price target raised to $7 from $5 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Ovid Therapeutics (OVID) to $7 from $5 and keeps an Outperform rating on the shares. The firm highlights multiple updates…
Ovid Therapeutics price target raised to $5 from $3 at Roth Capital
Roth Capital raised the firm’s price target on Ovid Therapeutics (OVID) to $5 from $3 and keeps a Buy rating on the shares. Phase 1 safety and tolerability results of…
Ovid Therapeutics Earnings Call Transcript: Q4 2025
Regulatory clearance for OV4071 and strong safety data for OV329 drive pipeline expansion into rare epilepsies, supported by $60M PIPE financing and a projected cash runway into 2029. New clinical trials and broad market opportunities are anticipated.
Ovid Therapeutics Annual report: Q4 2025
Ovid Therapeutics has published its Q4 2025 annual report on March 18, 2026.
Ovid Therapeutics Earnings release: Q4 2025
Ovid Therapeutics released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Ovid Therapeutics Slides: Q4 2025
Ovid Therapeutics has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 18, 2026.
Ovid Therapeutics announces Phase 1 clearance for OV4071
The Company will initiate a Phase 1 trial for OV4071, a potential first-in-class, oral, direct activator of potassium-chloride cotransporter 2 following Human Research Ethics Committee approval of the...